A Phase 3 interventional study of Denosumab and Zoledronic Acid in Bone Metastases, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by Amgen · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone metastases in subjects with advanced breast cancer.
725 studies on the registry are indexed under Fractures, Bone; 116 are open to participants now.
This study's enrollment of 2,049 is above the median of 80 across 458 interventional studies indexed under Fractures, Bone.
Browse Fractures, Bone studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Zoledronic Acid
Biological: Denosumab
Q4W 120 mg denosumab SC injection and 4 mg zoledronic acid (Zometa) placebo IV over a minimum of 15 minutes
Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
Also known as: Zometa
Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority)
Time to first on-study skeletal-related event (SRE) using a non-inferiority analysis. The median time to first skeletal-related event could not be estimated in one treatment arm, so the subject incidence is presented.
Time frame: Up to 34 months
Time to First On-Study Skeletal-Related Event (Superiority)
Time to first on-study skeletal-related event (SRE) using a superiority analysis. The median time to first skeletal-related event could not be estimated in one treatment arm, so the subject incidence is presented.
Time frame: Up to 34 months
Time to First and Subsequent On-Study Skeletal-Related Event
Time to first and subsequent on-study skeletal-related event (SRE) using a multiple event analysis. To be considered a subsequent SRE, the event must occur at least 21 days after the previous SRE. This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative number of events.
Time frame: Up to 34 months
Participants were enrolled from 27 April 2006 through 31 December 2007
| Milestone | Zoledronic Acid | Denosumab |
|---|---|---|
| Started | 1020 | 1026 |
| Received investigational product | 1014 | 1019 |
| Completed | 461 | 468 |
| Not completed | 559 | 558 |
| Withdrew: Death | 169 | 174 |
| Withdrew: Disease progression | 124 | 124 |
| Withdrew: Withdrawal by subject | 117 | 118 |
| Withdrew: Participant request | 57 | 61 |
| Withdrew: Adverse event | 43 | 28 |
| Withdrew: Physician decision | 15 | 14 |
| Withdrew: Noncompliance | 4 | 10 |
| Withdrew: Lost to follow-up | 7 | 8 |
| Withdrew: Protocol deviation | 0 | 2 |
| Withdrew: Ineligibility determined | 2 | 1 |
| Withdrew: Other | 21 | 18 |
Time to first on-study skeletal-related event (SRE) using a non-inferiority analysis. The median time to first skeletal-related event could not be estimated in one treatment arm, so the subject incidence is presented.
| Participants | Zoledronic Acid | Denosumab |
|---|---|---|
| Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority) | 372 | 315 |
Time to first on-study skeletal-related event (SRE) using a superiority analysis. The median time to first skeletal-related event could not be estimated in one treatment arm, so the subject incidence is presented.
| Participants | Zoledronic Acid | Denosumab |
|---|---|---|
| Time to First On-Study Skeletal-Related Event (Superiority) | 372 | 315 |
Time to first and subsequent on-study skeletal-related event (SRE) using a multiple event analysis. To be considered a subsequent SRE, the event must occur at least 21 days after the previous SRE. This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative number of events.
| Events | Zoledronic Acid | Denosumab |
|---|---|---|
| Time to First and Subsequent On-Study Skeletal-Related Event | 608 | 474 |
Collected over up to 2 years 10 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zoledronic Acid 4 mg Q4W | — | 471/1,013 (46.5%) | 941/1,013 (92.9%) |
| Denosumab 120 mg Q4W | — | 453/1,020 (44.4%) | 924/1,020 (90.6%) |
| Event | Zoledronic Acid 4 mg Q4W | Denosumab 120 mg Q4W |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 38/1013 | 53/1020 |
| Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 46/1013 | 47/1020 |
| AnaemiaBlood and lymphatic system disorders | 32/1013 | 27/1020 |
| VomitingGastrointestinal disorders | 31/1013 | 31/1020 |
| Metastases to liverNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 28/1013 | 20/1020 |
| PyrexiaGeneral disorders | 26/1013 | 21/1020 |
| PneumoniaInfections and infestations | 25/1013 | 20/1020 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 25/1013 | 24/1020 |
| DehydrationMetabolism and nutrition disorders | 24/1013 | 13/1020 |
| Hepatic failureHepatobiliary disorders | 16/1013 | 24/1020 |
| Event | Zoledronic Acid 4 mg Q4W | Denosumab 120 mg Q4W |
|---|---|---|
| NauseaGastrointestinal disorders | 377/1013 | 350/1020 |
| FatigueGeneral disorders | 323/1013 | 291/1020 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 289/1013 | 246/1020 |
| Back painMusculoskeletal and connective tissue disorders | 256/1013 | 238/1020 |
| Bone painMusculoskeletal and connective tissue disorders | 233/1013 | 181/1020 |
| PyrexiaGeneral disorders | 231/1013 | 157/1020 |
| VomitingGastrointestinal disorders | 225/1013 | 199/1020 |
| DiarrhoeaGastrointestinal disorders | 198/1013 | 223/1020 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 221/1013 | 199/1020 |
| AnaemiaBlood and lymphatic system disorders | 217/1013 | 183/1020 |
| Age, Continuous(Years) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Mean | 56.6 ± 11.6 | 56.8 ± 11.5 | 56.7 ± 11.5 |
| Sex: Female, Male(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Female | 1011 | 1018 | 2029 |
| Male | 9 | 8 | 17 |
| Race/Ethnicity, Customized(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| White or Caucasian | 813 | 822 | 1635 |
| Black or African American | 25 | 26 | 51 |
| Hispanic or Latino | 59 | 59 | 118 |
| Asian | 37 | 32 | 69 |
| Japanese | 69 | 70 | 139 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Other | 16 | 16 | 32 |
| Previous Skeletal-Related Event Stratification Factor(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Yes | 373 | 378 | 751 |
| No | 647 | 648 | 1295 |
| Prior Oral Bisphosphonate Use Stratification Factor(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Yes | 38 | 42 | 80 |
| No | 982 | 984 | 1966 |
| Current Chemotherapy Stratification Factor(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Yes | 408 | 410 | 818 |
| No | 612 | 616 | 1228 |
| Japan Stratification Factor(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Yes | 67 | 69 | 136 |
| No | 953 | 957 | 1910 |
No study locations are listed for this record.
Ran from Apr 2006 to primary completion in Jul 2009, 39 months.
Results were first posted in Mar 2014, 4 years 7 months after primary completion. A results delay was requested in Jun 2010.
Of 14 phase 3 interventional studies under Fractures, Bone, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 46. This study's 39 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab